ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

ClinicalTrials.gov ID: NCT00679172

Public ClinicalTrials.gov record NCT00679172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC-ssaV-) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA.

Study identification

NCT ID
NCT00679172
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Emergent BioSolutions
Industry
Enrollment
187 participants

Conditions and interventions

Conditions

Interventions

  • Dose of 1.1 x 10^10 CFU (Cohort 3) Biological
  • Dose of 5.0 x 10^9 CFU (Cohort 1) Biological
  • Dose of 7.5 x 10^9 CFU (Cohort 2) Biological
  • Dose of of 1.7 x 10^10 CFU (Cohort 4) Biological
  • Placebo (Cohorts 1-4 pooled) Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2008
Primary completion
Nov 30, 2008
Completion
Nov 30, 2008
Last update posted
Apr 8, 2024

2008

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Miami Research Associates South Miami Florida 33143
John Hopkins Bloomberg School of Public Health Baltimore Maryland 21205
Unit of Infectious Diseases, University of Vermont College of Medicine Burlington Vermont 05405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00679172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 8, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00679172 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →